INmune Bio and Quantum Computing, known as QCi, have agreed to collaborate using quantum computing, AI, and data analytics to explore new indications for XPro (XPro1595), an investigational treatment for Alzheimer’s disease and other medical conditions.
The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the first stage of the project, the companies will analyse clinical and publicly accessible biomedical datasets to identify conditions sharing the biological mechanisms targeted by XPro.
The agreement also includes options for additional work as clinical programmes progress.
Researchers will combine INmune Bio’s findings from pre-clinical studies and four clinical trials with QCi’s Dirac-3S entropy quantum optimisation machine.
The hardware runs at room temperature and low power, avoiding the specialised cooling systems used by alternative quantum platforms.
The teams will benchmark the quantum machine against standard statistical and machine-learning tools to assess which computational method is best suited for each stage of analysis, while working to build a repeatable discovery model.
INmune Bio CEO David Moss said: “We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro. This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analysing large data sets.
“We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying paediatric approvals may earn a Priority Review Voucher.”
XPro is engineered to neutralise soluble tumour necrosis factor, reducing neuroinflammation whilst preserving protective immune defences.
The therapy holds fast track designation from the US Food and Drug Administration (FDA) and has completed an End-of-Phase II regulatory meeting, positioning it for an integrated Phase IIb/III trial in early Alzheimer’s disease.
Additionally, INmune Bio is developing CORDStrom, a mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa.
Regulatory filings for CORDStrom are scheduled with the UK Medicines and Healthcare products Regulatory Agency in 2026, the European Medicines Agency in 2027, and the US FDA.
